Prestige Consumer Healthcare Inc. · NYSE:PBH
Prestige Consumer Healthcare — Q3 2025 Earnings Presentation
17 slides from Prestige Consumer Healthcare's earnings presentation, Feb 6, 2025
Slide 1: Third Quarter FY 2025 Results
Third Quarter FY 2025 Results February 6th, 2025
Slide 2: Safe Harbor Disclosure
Safe Harbor Disclosure This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company’s expected financial performance, including revenues, organic revenue growth, adjusted diluted E
Slide 3: Agenda for Today's Discussion
Agenda for Today’s Discussion I. Performance Update II. Financial Overview III. FY25 Outlook THIRD QUARTER FY25 RESULTS 3
Slide 4: I. Performance Update
I. Performance Update THIRD QUARTER FY25 RESULTS
Slide 5: Record Results in Third Quarter FY 25
Record Results in Third Quarter FY 25 ◼ Record quarterly revenue of $290.3 million, ahead of expectations Q3 FY 25 Sales ◼ Outperformance highlighted by strong International growth Drivers ◼ Positive trends in Women’s Health and Clear Eyes®, as expected ◼ Gross Margin performance stable Superior Ear
Slide 6: Comprehensive GI Portfolio Highlights Brand-Building Capabilities
Comprehensive GI Portfolio Highlights Brand-Building Capabilities Iconic GI KeySolutions Drivers Brand-Building DrivingDriving Brand-Building Category LeadershipGrowth Consumption & Growth Campaigns & Content Insight Driven Innovation #1 Motion sickness & nausea brand at retail1 Delivering on consum
Slide 7: II. Financial Overview
II. Financial Overview THIRD QUARTER FY25 RESULTS
Slide 8: Third Quarter and YTD FY25 Performance Highlights
Third Quarter and YTD FY25 Performance Highlights FY25 FY24 2.7% Record revenue of $290.3 million, up 2.7% vs. PY $290.3 $282.7 5.0% Q3 $ 98.5 $93.8 15.1% $1.22 $1.06 (2) Revenue EBITDA Diluted EPS EBITDA(3) of $98.5 million, up 5.0% vs. PY (0.8%) $841.2 $848.4 (4.7%) YTD $270.0 $283.4 0.3% Record E
Slide 9: FY25 Third Quarter and YTD Consolidated Financial Summary
FY25 Third Quarter and YTD Consolidated Financial Summary 3 Months Ended 9 Months Ended YTD FY25 Comments Q3 FY 25 Q3 FY 24 % Chg YTD FY 25 YTD FY 24 % Chg ◼ Organic Revenue(1) down 0.9% vs. prior year Total Revenue $ 290.3 $ 282.7 2.7% $ 841.2 $ 848.4 (0.8%) – Clear Eyes sales aligned to expectatio
Slide 10: Industry Leading Free Cash Flow Trends
Industry Leading Free Cash Flow Trends Free Cash Flow(2) Comments Q3 FY25 Q3 FY24 YTD FY25 YTD FY24 ◼ YTD FY25 Free Cash Flow(2) of $184.9 million up 5% vs. prior year 5.3% – Maintaining full-year free cash flow outlook(4) of $184.9 $240 million or more $175.6 – Strong business attributes continue t
Slide 11: III. FY25 Outlook
III. FY25 Outlook THIRD QUARTER FY25 RESULTS
Slide 12: Raising FY 25 Earnings Outlook
Raising FY 25 Earnings Outlook ◼ Remain well-positioned in dynamic macro environment ◼ Continue to emphasize brand-building on leading brands Top Line Trends ◼ Revenues of $1,128 to $1,132 million — Organic growth of approximately 1% ex-FX ◼ Adjusted Diluted EPS(5) of approximately $4.50 EPS – Incre
Slide 13: Q&A
Q&A THIRD QUARTER FY25 RESULTS
Slide 14: Appendix
Appendix (1) Organic Revenue is a Non-GAAP financial measure and is reconciled to the most closely related GAAP financial measure in the attached Reconciliation Schedules and / or our earnings release dated February 6, 2025 in the “About Non-GAAP Financial Measures” section. (2) Adjusted Diluted EPS
Slide 15: Reconciliation Schedules
Reconciliation Schedules Organic Revenue Change EBITDA Margin THIRD QUARTER FY25 RESULTS 15
Slide 16: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Adjusted Net Income & Adjusted Diluted EPS (a) Income tax adjustment to adjust for discrete income tax items. Adjusted Free Cash Flow THIRD QUARTER FY25 RESULTS 16
Slide 17: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Projected Adjusted EPS Projected FY'25 GAAP Diluted EPS $ 4.58 Adjustments: Normalized tax rate adjustment (a) (0.08) Projected FY'25 Non-GAAP Adjusted EPS $ 4.50 (a) Income tax adjustment to adjust for discrete income tax items. Projected Free Cash Flow THIRD QU
Prestige Consumer Healthcare — Q3 2025 Earnings Presentation on 6ix